Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Faergeman

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Atherosclerosis|April 13, 2005
The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish populationDorte Damgaard, Mogens L Larsen, Peter H Nissen, et al.
International Journal of Cardiology|September 5, 2013
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levelsMatti J Tikkanen, Rana Fayyad, Ole Faergeman, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|April 1, 2011
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL studyAnders G Olsson, Christina Lindahl, Ingar Holme, et al.
Atherosclerosis|March 31, 2009
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)Ingar Holme, Timo E Strandberg, Ole Faergeman, et al.
Annals of Medicine|January 23, 2009
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)Ingar Holme, Nilo B Cater, Ole Faergeman, et al.
Food Science & Nutrition|June 8, 2018
Enhancing the fatty acid profile of milk through forage-based rations, with nutrition modeling of diet outcomesCharles M Benbrook, Donald R Davis, Bradley J Heins, et al.
The American Journal of Cardiology|May 12, 2009
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarctionTimo E Strandberg, Ingar Holme, Ole Faergeman, et al.
The American Journal of Cardiology|September 18, 2004
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering studyTerje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|March 27, 2009
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme, Michael Szarek, Nilo B Cater, et al.
Circulation. Cardiovascular Genetics|February 5, 2010
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patientsCraig L Hyde, Alan Macinnes, Frances A Sanders, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Atherosclerosis|April 13, 2005
The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish populationDorte Damgaard, Mogens L Larsen, Peter H Nissen, et al.
International Journal of Cardiology|September 5, 2013
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levelsMatti J Tikkanen, Rana Fayyad, Ole Faergeman, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|April 1, 2011
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL studyAnders G Olsson, Christina Lindahl, Ingar Holme, et al.
Atherosclerosis|March 31, 2009
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)Ingar Holme, Timo E Strandberg, Ole Faergeman, et al.
Annals of Medicine|January 23, 2009
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)Ingar Holme, Nilo B Cater, Ole Faergeman, et al.
Food Science & Nutrition|June 8, 2018
Enhancing the fatty acid profile of milk through forage-based rations, with nutrition modeling of diet outcomesCharles M Benbrook, Donald R Davis, Bradley J Heins, et al.
The American Journal of Cardiology|May 12, 2009
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarctionTimo E Strandberg, Ingar Holme, Ole Faergeman, et al.
The American Journal of Cardiology|September 18, 2004
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering studyTerje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|March 27, 2009
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme, Michael Szarek, Nilo B Cater, et al.
Circulation. Cardiovascular Genetics|February 5, 2010
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patientsCraig L Hyde, Alan Macinnes, Frances A Sanders, et al.
Pageof 6